Trials that use: Multiple imputation / missing data
New to this method? Read the tutorial →
20,324 results
- FUTR-30Independent statistical analysis of Discharge Follow-up Phone Call Program: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03050918).
- FUTUREIndependent statistical analysis of Study to Evaluate the Efficacy and Safety of FOLFOX-4 Plus Cetuximab Versus UFOX Plus Cetuximab.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- FUTURE 2Independent statistical analysis of Bosentan in Children With Pulmonary Arterial Hypertension Extension Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00319020).
- FUTURE 3 ExtIndependent statistical analysis of FUTURE 3 Study Extension: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01338415).
- FX-322 in Sensorineural Hearing Loss: Complete Statistical AnalysisIndependent statistical analysis of FX-322 in Sensorineural Hearing Loss: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03616223).
- FX-LEARNIndependent statistical analysis of AFQ056 for Language Learning in Children With FXS: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02920892).
- G-BMTIndependent statistical analysis of Buprenorphine Group Medical Visits in Primary Care: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02526212).
- G-CAREIndependent statistical analysis of Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- G-CSF PMRDIndependent statistical analysis of G-CSF PMRD: Granulocyte Colony Stimulating Factor (G-CSF) Stimulated Bone Marrow and In Vivo T-Cell Depletion in Patients With Hematologic Malignancies or Bone Marrow Failure Syndrome: primary endpoint results,…
- G-MINORIndependent statistical analysis of Genomics in Michigan Impacting Observation or Radiation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02783950).
- G-Pen™ for Hypoglycemia Rescue in T1D Patients: Complete Statistical AnalysisIndependent statistical analysis of G-Pen™ for Hypoglycemia Rescue in T1D Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02423980).
- G2YMIIndependent statistical analysis of Getting to Yes, Michigan! (G2YMI): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05096260).
- GA YAZ ACNE in China Phase III: Complete Statistical AnalysisIndependent statistical analysis of GA YAZ ACNE in China Phase III: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00818519).
- GA-68Independent statistical analysis of Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01619865).
- GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence: Complete Statistical AnalysisIndependent statistical analysis of GABA Mechanisms Underlying the Vulnerability to Alcohol Dependence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00611767).
- Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD): Complete Statistical AnalysisIndependent statistical analysis of Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01138124).
- Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin for Insomnia Symptoms and Nighttime Vasomotor Symptoms (VMS) in Peri- and Postmenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Gabapentin for Perioperative Pain Relief in Surgical Abortion: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin for Perioperative Pain Relief in Surgical Abortion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04292171).
- Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin for Post-Operative Pain Control and Narcotic Reduction in Scrotal Surgery: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gabapentin for Postop Pain After SSLF: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin for Postop Pain After SSLF: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03123861).
- Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00880191).
- Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin on Postoperative Pain Associated With Ureteroscopy and Stents Insertion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03151746).
- Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP): Complete Statistical AnalysisIndependent statistical analysis of Gabapentin to Improve Patient Tolerance in Endoscopic Retrograde Cholangiopancreatography (ERCP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01143766).
- Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients: Complete Statistical AnalysisIndependent statistical analysis of Gabapentin Treatment of Benzodiazepine Abuse in Methadone Maintenance Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00420771).
- GABLEIndependent statistical analysis of Postoperative Chemoradiation or Chemotherapy After Preoperative Chemotherapy for Gastric Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03515941).
- GADIndependent statistical analysis of Drug Treatment Validation of Functional Magnetic Resonance Imaging in Generalized Anxiety Disorder: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GadaCAD 1Independent statistical analysis of Gadobutrol/Gadavist-enhanced Cardiac Magnetic Resonance Imaging (CMRI) to Detect Coronary Artery Disease (CAD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GADinLADAIndependent statistical analysis of Injections of Glutamic Acid Decarboxylase (GAD) for LADA Type of Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age: Complete Statistical AnalysisIndependent statistical analysis of Gadopiclenol Pharmacokinetics, Safety and Efficacy in Children < 2 Years of Age: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GAINIndependent statistical analysis of Improving HIV Diagnosis, Linkage to Care, and Prevention Services With HIV Point-of-Care Nucleic Acid Tests: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- GAINIndependent statistical analysis of Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer’s Disease: Complete Statistical AnalysisIndependent statistical analysis of GAIN Trial: Phase 2/3 Study of COR388 in Subjects With Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GAINS-2Independent statistical analysis of A Brief Cognitive Task Intervention for NHS Staff Affected by COVID-19 Trauma (GAINS-2 Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- GALACTIC-HFIndependent statistical analysis of GALACTIC-HF, the randomized phase 3 trial of omecamtiv mecarbil in chronic heart failure with reduced ejection fraction, including time-to-event methods, KCCQ analysis, confidence intervals, multiplicity, and safety.
- GalaNicIndependent statistical analysis of Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02420327).
- Galantamine Effects on Cognitive Function in Abstinent Cocaine Users: Complete Statistical AnalysisIndependent statistical analysis of Galantamine Effects on Cognitive Function in Abstinent Cocaine Users: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00606801).
- GALAXYIndependent statistical analysis of Long-term Evaluation of the Linox Family ICD Leads Registry (GALAXY): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00836589).
- Galcanezumab for Vestibular Migraine: Complete Statistical AnalysisIndependent statistical analysis of Galcanezumab for Vestibular Migraine: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04417361).
- GALILEO-4DIndependent statistical analysis of Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed…
- Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of Gallium-68 PSMA-11 PET Imaging in Prostate Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03803475).
- Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence: Complete Statistical AnalysisIndependent statistical analysis of Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- GAM 10-06Independent statistical analysis of Non-Interventional Study on the Tolerability and Efficacy of IVIG: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02303093).
- GAMES-PILOTIndependent statistical analysis of Glyburide Advantage in Malignant Edema and Stroke Pilot: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01268683).
- GameSquad for Adults With Down Syndrome: Complete Statistical AnalysisIndependent statistical analysis of GameSquad for Adults With Down Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05473247).
- GAMINIIIndependent statistical analysis of Gut and Azithromycin Mechanisms in Infants and Children II: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04315272).
- Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer: Complete Statistical AnalysisIndependent statistical analysis of Gamma Secretase Inhibitor RO4929097 in Previously Treated Metastatic Pancreas Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01232829).
- Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study: Complete Statistical AnalysisIndependent statistical analysis of Gamma-Amino Butyric Acid (GABA)-A Alpha2/3 Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00129441).
- GammozIndependent statistical analysis of Effect of Gamma Tocopherol Enriched Supplementation on Response to Inhaled O3 Exposure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Ganaxolone Treatment in Children With Fragile X Syndrome: Complete Statistical AnalysisIndependent statistical analysis of Ganaxolone Treatment in Children With Fragile X Syndrome: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01725152).
- GANDRIndependent statistical analysis of Revolutionizing Normative Re-education: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04356261).